Teva Gets Fed. Circ. To Affirm Thyroid Patent Is Indefinite

Law360 (July 31, 2020, 9:02 PM EDT) -- A Delaware federal judge rightly found that claims of a patent covering the thyroid drug Tirosint are invalid as indefinite, the Federal Circuit affirmed Friday in a win for Teva Pharmaceuticals USA Inc.

The patent for IBSA Pharma Inc.'s drug features the term "half-liquid," which the three-judge panel affirmed doesn't have a set meaning in either the patent specification, its priority application or scientific literature. The precedential opinion upholds U.S. District Judge Richard G. Andrews' finding that the claims are indefinite under Section 112 of the Patent Act.

The patent otherwise would have expired in 2024, according to the U.S. Food...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!